138results about How to "Reduce the number of injections" patented technology

The invention discloses a film transistor and a manufacturing method thereof. The manufacturing method comprises the following steps: manufacturing a buffer layer on a substrate; manufacturing a polycrystalline silicon layer after ion doping on the buffer layer, wherein the concentrations of doped ions of the polycrystalline silicon layer after ion doping is distributed in a high-to-low gradient manner from the upper surface to the lower surface of the polycrystalline silicon layer; etching the polycrystalline silicon layer to form a concave silicon island, wherein the sunken part of the concave silicon island is a channel region, and a convex part is a source drain region; successively forming a gate-insulation layer, a gate layer, an interlayer insulation layer and a source drain electrode on the concave silicon island. The film transistor and the manufacturing method thereof, disclosed by the invention, have the advantages that an ion implantation technology is adopted, or the doping concentration is controlled in a PECVD (plasma enhanced chemical vapor deposition) technology, so that the purpose of the vertical gradient of the density of the doped ions is realized, and the number of times of implanting the ions is omitted or reduced; besides, the number of photomasks in a film transistor technology can be reduced, and the process complexity is reduced; in addition, the vertical concentration gradient can form an LDD (laser detector diode) structure, so that TFT (thin film transistor) leak currents are reduced.

The invention discloses a recombinant human chorionic gonadotrophin-Fc fusion protein (HCG-Fc for short) and a preparation method thereof. The HCG-Fc protein is a dimerized fusion protein, and the amino acid sequence of the fusion protein sequentially comprises an HCG beta subunit, an HCG alpha subunit, a flexible peptide joint and a human IgG Fc mutant from an N end to a C end. Compared with the existing chorionic gonadotrophin, the fusion protein has longer in-vivo half life, higher bioavailability and lower side effect. The invention also relates to an application of a recombinant HCG-Fc fusion protein composition in preparation of medicaments for treating and / or preventing infertility.